iCell Cardiomyocytes DCM LMNA L35P, 01016 and Isogenic Control

Accurately model the pathophysiology of dilated cardiomyopathy (DCM) with LMNA L35P-mutant iCell® Cardiomyocytes and isogenic controls.

  • Industry-leading With the most peer-reviewed publications and protocols, iCell Cardiomyocytes are the in vitro gold standard.
  • Reproducible research Stringent quality control and >90% cardiomyocyte purity ensure consistent performance with every batch.
  • Disease relevance Displaying the classic hallmarks of DCM, these cells support research into functional cardiac consequences.
  • Isogenic control Derived from the same induced pluripotent stem cell (iPSC) background, a gene-corrected control enables direct comparison.
  • Simple implementation Specially formulated media maximizes viability at thaw and beyond, enabling acute and subchronic studies.
Catalog # GCMCL35P01016

Products

Kits

  • Cryopreserved iCell L35P Cardiomyocytes, 01016
  • 30 ml Plating Medium
  • 100 ml Maintenance Medium
  • User’s Guide

genetic status

Quantity (Cells Per Vials)

Catalog #

Catalog #:

Dilated Cardiomyopathy differentiated from human iPS cells, frozen

From
$1,056.00

Cells Only

  • Cryopreserved iCell L35P Cardiomyocytes, 01016
  • User’s Guide

genetic status

Quantity (Cells Per Vials)

Catalog #

Catalog #:

Dilated Cardiomyopathy differentiated from human iPS cells, frozen

From
$956.00

Product Overview

Lamin A/C LMNA mutations are a common cause of dilated cardiomyopathy (DCM). Clinically, DCM is characterized by ventricular dilation concurrent with reduced systolic function and arrhythmias. A missense mutation in the gene encoding the lamin A/C protein (LMNA) results in a change of amino acid 35 from leucine-to-proline (L35P).

To enable researchers to study functional cardiac consequences, somatic cells from an individual carrying the LMNA L35P mutation were reprogrammed to generate iCell® Cardiomyocytes DCM (L35P), 01016. In addition, an isogenic control, iCell Cardiomyocytes Corrected DCM (L35P), was generated using genome engineering strategies to correct the mutation. iCell Cardiomyocytes (L35P) display classic hallmarks of dilated cardiomyopathy including abnormal contractile properties (i.e. reduced contraction amplitude).

Best-in-Class Biology

iCell Cardiomyocytes (L35P) and its isogenic control (L35P Corrected) exhibit the relevant biology and functionality to advance research and preclinical studies for devastating congenital muscular dystrophies, laminopathies, and cardiomyopathies.

  • Fully differentiated, >90% pure cardiomyocytes
  • Expression of relevant cardiac markers (e.g. cTNT, ACTN2)
  • Isogenic control available

Components:

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Technical Docs

PROTOCOLS

Performance Data

Comparison of iCell Cardiomyocytes (L35P) and Isogenic Control

Representative phase contrast images (20X) of isogenic control and iCell Cardiomyocytes (L35P) reveal comparable structure when plated at 20,000 cells per well in 96-well format. (DIV14)

Figure 1: Morphology Assessment

Figure 2: Contractility Measurements (Impedance)

Contractility Measurements (Impedance)

Contractility was monitored by measuring impedance over time. iCell Cardiomyocytes (L35P) display reduced contraction amplitude relative to isogenic control. (DIV 14)

Calcium Handling Assessment

Representative calcium transients reveal that iCell Cardiomyocytes (L35P) display increase beat rate relative to isogenic control. (DIV 14)

Figure 3: Calcium Handling Assessment

Publications